Literature DB >> 23829510

A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.

Fabiana Ostronoff1, Megan Othus, Hagop M Kantarjian, Soheil Meshinchi, Farhad Ravandi, Paul C Hendrie, Stefan Faderl, Pamela S Becker, Jorge E Cortes, John M Pagel, Stephen H Petersdorf, John E Godwin, Cheryl L Willman, Sherry A Pierce, Alan F List, Ravinder K Sandhu, Roland B Walter, Derek L Stirewalt, Frederick R Appelbaum, Elihu H Estey.   

Abstract

Entities:  

Keywords:  FLT3-ITD; NPM1; acute myeloid leukaemia; model; prediction

Mesh：

Substances：

Year:  2013        PMID： 23829510      PMCID： PMC4128010          DOI： 10.1111/bjh.12450

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).

Authors:  J E Godwin; K J Kopecky; D R Head; C L Willman; C P Leith; H E Hynes; S P Balcerzak; F R Appelbaum
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

2.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

3.  Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

Authors:  Salut Brunet; Myriam Labopin; Jordi Esteve; Jan Cornelissen; Gerard Socié; Anna P Iori; Leo F Verdonck; Liisa Volin; Alois Gratwohl; Jorge Sierra; Mohamad Mohty; Vanderson Rocha
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

4.  The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials.

Authors:  P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

5.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

Authors:  Susanne Schnittger; Claudia Schoch; Wolfgang Kern; Cristina Mecucci; Claudia Tschulik; Massimo F Martelli; Torsten Haferlach; Wolfgang Hiddemann; Brunangelo Falini
Journal:  Blood       Date:  2005-08-02       Impact factor: 22.113

Review 6.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

7.  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.

Authors:  Stephen H Petersdorf; Kenneth J Kopecky; Marilyn Slovak; Cheryl Willman; Thomas Nevill; Joseph Brandwein; Richard A Larson; Harry P Erba; Patrick J Stiff; Robert K Stuart; Roland B Walter; Martin S Tallman; Leif Stenke; Frederick R Appelbaum
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

8.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Authors:  D Grimwade; H Walker; F Oliver; K Wheatley; C Harrison; G Harrison; J Rees; I Hann; R Stevens; A Burnett; A Goldstone
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

9.  Phase II evaluation of an intensified induction therapy with standard daunomycin and cytarabine followed by high dose cytarabine for adults with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (SWOG-9500).

Authors:  Stephen H Petersdorf; Cathryn Rankin; David R Head; Howard R Terebelo; Cheryl L Willman; Stanley P Balcerzak; Anand B Karnad; Shaker R Dakhil; Frederick R Appelbaum
Journal:  Am J Hematol       Date:  2007-12       Impact factor: 10.047

10.  Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.

Authors:  Jeanne E Anderson; Kenneth J Kopecky; Cheryl L Willman; David Head; Margaret R O'Donnell; Frederick W Luthardt; Thomas H Norwood; I-Ming Chen; Stanley P Balcerzak; David B Johnson; Frederick R Appelbaum
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.